Q3 2025 Earnings Estimate for Corcept Therapeutics Incorporated (NASDAQ:CORT) Issued By Zacks Research

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research lifted their Q3 2025 earnings per share estimates for Corcept Therapeutics in a report released on Wednesday, April 17th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $0.26 per share for the quarter, up from their previous estimate of $0.25. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.92 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.40 EPS, FY2025 earnings at $1.14 EPS and Q1 2026 earnings at $0.39 EPS.

Other equities research analysts also recently issued research reports about the company. Truist Financial upped their price target on Corcept Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, February 16th. HC Wainwright dropped their price objective on Corcept Therapeutics from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, January 2nd. Finally, StockNews.com downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $37.30.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $22.66 on Thursday. The stock’s 50-day moving average is $23.93 and its two-hundred day moving average is $25.51. Corcept Therapeutics has a 1-year low of $20.87 and a 1-year high of $34.28. The company has a market cap of $2.35 billion, a price-to-earnings ratio of 23.85 and a beta of 0.48.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Thursday, February 15th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.03. Corcept Therapeutics had a return on equity of 21.98% and a net margin of 21.86%. The firm had revenue of $135.41 million for the quarter, compared to analyst estimates of $129.27 million. During the same quarter in the prior year, the company earned $0.14 EPS. Corcept Therapeutics’s revenue was up 31.4% on a year-over-year basis.

Insider Buying and Selling

In related news, insider Joseph Douglas Lyon sold 5,443 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $26.00, for a total transaction of $141,518.00. Following the transaction, the insider now owns 7,314 shares in the company, valued at approximately $190,164. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $25.30, for a total transaction of $55,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joseph Douglas Lyon sold 5,443 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $26.00, for a total value of $141,518.00. Following the sale, the insider now directly owns 7,314 shares of the company’s stock, valued at $190,164. The disclosure for this sale can be found here. Insiders have sold 83,783 shares of company stock worth $2,118,996 in the last quarter. 19.80% of the stock is owned by insiders.

Institutional Trading of Corcept Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CORT. JPMorgan Chase & Co. lifted its position in Corcept Therapeutics by 2.4% during the 1st quarter. JPMorgan Chase & Co. now owns 216,081 shares of the biotechnology company’s stock worth $4,866,000 after acquiring an additional 5,036 shares during the period. American Century Companies Inc. lifted its holdings in shares of Corcept Therapeutics by 8.2% in the 1st quarter. American Century Companies Inc. now owns 88,553 shares of the biotechnology company’s stock valued at $1,994,000 after buying an additional 6,684 shares during the period. Citigroup Inc. lifted its holdings in shares of Corcept Therapeutics by 15.0% in the 1st quarter. Citigroup Inc. now owns 103,241 shares of the biotechnology company’s stock valued at $2,325,000 after buying an additional 13,488 shares during the period. Natixis Advisors L.P. lifted its holdings in shares of Corcept Therapeutics by 56.7% in the 1st quarter. Natixis Advisors L.P. now owns 18,581 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 6,726 shares during the period. Finally, Acadian Asset Management LLC lifted its holdings in shares of Corcept Therapeutics by 3.3% in the 1st quarter. Acadian Asset Management LLC now owns 31,845 shares of the biotechnology company’s stock valued at $716,000 after buying an additional 1,032 shares during the period. 93.61% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.